Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.
You may also be interested in...
Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders
Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.
Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders
Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.
Pfizer Launches Phase III Trial For Sutent In Non-Small Cell Lung Cancer
Positive preliminary Phase II results on sunitinib/erlotinib combination therapy were presented at major lung cancer meeting this week in South Korea.